Zhihua Wang,li Qin,Chunyan Zhang,Yuyan Ma. Effect of IL-12 on the proliferation and cytotoxicity of CIK cells to gastric adenocarcinoma cell BGC-823. Oncol Transl Med, 2014, 13: 355-359.
Effect of IL-12 on the proliferation and cytotoxicity of CIK cells to gastric adenocarcinoma cell BGC-823
Received:July 01, 2014  Revised:July 28, 2014
View Full Text  View/Add Comment  Download reader
KeyWord:Cytokine-induced killer (CIK) cell; interleukin-12 (IL-12); proliferative ability; cytotoxicity
Author NameAffiliationE-mail
Zhihua Wang Hefei Fenghuang Tumor Hospital, Hefei 267800, China
Cancer Research Institute of Harbin Medical University, Harbin 150081, China 
hljwzh000@163.com 
li Qin Cancer Research Institute of Harbin Medical University, Harbin 150081, China  
Chunyan Zhang Cancer Research Institute of Harbin Medical University, Harbin 150081, China  
Yuyan Ma Cancer Research Institute of Harbin Medical University, Harbin 150081, China  
Hits: 4379
Download times: 5782
Abstract:
      Objective: The aim of the study was to evaluate the effect of interleukin-12 (IL-12) on the proliferation and cytotoxicity of cytokine-induced killer (CIK) cells in vitro. Methods: Three different combinations of cytokines, IL-2, IL-12 IL-2, and IL-12, were used to proliferate CIK cells, adding IFN-γ, IL-1 and CD3 McAb in each one. Phenotype of the cells was analyzed by flow cytometry. The cellular proliferation and cytotoxic activity were determined by cytometry and MTT assay. Results: CIK cells generated by the three methods showed high reproductive activity, and no obviously difference in inducing CD3 CD56 cells was found among the three groups. The group of IL-2 IL-12 evidently enhanced both the proliferation and the cytotoxicity of the CIK cells compared with the other two groups (P < 0.05). Conclusion: IL-12 could be used to induce the CIK cells as well as IL-2. CIK cells induced by combining IL-12 with IL-2 had stronger proliferative ability and higher cytotoxicity to tumor cells in vitro, which could be used as a potential anti-tumor adoptive immunotherapy in clinic.
Close